IAA/BSA is an antigen-adjuvant conjugate formed by linking IAA with bovine serum albumin (BSA). Conjugating the antigen with a protein adjuvant enhances the production of antigen-specific antibodies in vaccine models. The conjugate does not alter protein folding or disrupt primary epitopes, and it can improve cross-presentation and the production of antigen-specific T cells.